Indication : For the Management of Dyslipidemia.
Dyslipidemia a condition characterized by an abnormal level of lipids (such as cholesterol, triglycerides, LDL, and HDL) in the blood, which can increase the risk of cardiovascular disease, including heart attacks, strokes, and peripheral artery disease.
MOA : It is a selective and competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts -3-hydroxy-3- methyl glutaryl coenzyme A to mevalonate, a precursor of cholesterol
